A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens

Trial Profile

A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 10 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top